Tags

Type your tag names separated by a space and hit enter

Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Am J Obstet Gynecol. 2020 Jun 17 [Online ahead of print]AJ

Abstract

BACKGROUND

Since 2013, the residents of the city of Vantaa, Finland, have been offered their first long-acting reversible contraceptive method (levonorgestrel-releasing intrauterine system, implant, and copper intrauterine device) free of charge.

OBJECTIVE

The primary aim of this study was to assess the 2-year cumulative discontinuation rates of long-acting reversible contraceptive methods when provided free of charge for first-time users in a real-world setting. Additional aims were to describe factors associated with discontinuation and to evaluate the reasons for discontinuation.

STUDY DESIGN

This is a retrospective register-based cohort study of 2026 nonsterilized women aged 15 to 44 years, who initiated a free-of-charge long-acting contraceptive method in 2013-2014 in the city of Vantaa. Removals within 2 years after method initiation and reasons for discontinuation were obtained from electronic health records and from national registers. We calculated the 2-year cumulative incidence rates of discontinuation with 95% confidence intervals for each method. Furthermore, we assessed crude and adjusted incidence rate ratios of discontinuation with 95% confidence interval by Poisson regression models comparing implants and copper intrauterine device with levonorgestrel-releasing intrauterine systems.

RESULTS

During the 2 -year follow-up, 514 women discontinued, yielding a cumulative discontinuation rate of 28.3 per 100 women-years (95% confidence interval, 26.2-30.4). Among the 1199 women who initiated the levonorgestrel-releasing intrauterine system, the cumulative discontinuation rate was 24.2 per 100 women-years (95% confidence interval, 21.7-26.9); among the 642 implant users, 33.3 per 100 women-years (95% confidence interval, 29.5-37.4); and among the 185 copper intrauterine device users, 37.8 per 100 women-years (95% confidence interval, 31.0-45.7). Compared with women aged 30 to 44 years, women aged 15 to 19 years (adjusted incidence rate ratio, 1.58; 95% confidence interval, 1.17-2.14) and 20 to 29 years (adjusted incidence rate ratio, 1.35; 95% confidence interval, 1.11-1.63) were more likely to discontinue. We observed a higher discontinuation rate in women who had given birth within the previous year (adjusted incidence rate ratio, 1.36; 95% confidence interval, 1.13-1.65), spoke a native language other than Finnish or Swedish (adjusted incidence rate ratio, 1.31; 95% confidence interval, 1.06-1.63), and had a history of a sexually transmitted infection (adjusted incidence rate ratio, 1.62; 95% confidence interval, 1.07-2.46). No association was found in marital status, overall parity, history of induced abortion, socioeconomic status, education level, or smoking status. The most common reason for discontinuation was bleeding disturbances, reported by 21% of women who discontinued the levonorgestrel-releasing intrauterine system, by 71% who discontinued the implant, and by 41% who discontinued the copper intrauterine device. One in 4 women who discontinued the copper intrauterine device reported heavy menstrual bleeding, whereas only 1% who discontinued the levonorgestrel-releasing intrauterine system and none who discontinued implants reported this reason. Abdominal pain was the reported reason for discontinuation in 20% of both intrauterine device users and in only 2% who discontinued implants.

CONCLUSION

At 2 years, the use of implants and copper intrauterine devices was more likely to be discontinued than that of the levonorgestrel-releasing intrauterine system. Women younger than 30 years and those who gave birth in the preceding year, spoke a native language other than Finnish or Swedish, or had a history of sexually transmitted infections were more likely to discontinue. The levonorgestrel-releasing intrauterine system was least likely to be removed owing to bleeding disturbances.

Authors+Show Affiliations

Department of General Practice and Primary Care, University of Helsinki, Helsinki, Finland; Health Center, City of Vantaa, Finland.Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland; Health Center, City of Vantaa, Finland.Biostatistics Consulting, Department of Public Health, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.Finnish Institute for Health and Welfare, Helsinki, Finland, and Karolinska Institute, Stockholm, Sweden.Department of General Practice and Primary Care, University of Helsinki and Helsinki University Hospital, and Research Center Folkhälsan, Helsinki, Finland.Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: oskari.heikinheimo@helsinki.fi.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32562657

Citation

Saloranta, Tuire H., et al. "Free-of-charge Long-acting Reversible Contraception: Two-year Discontinuation, Its Risk Factors, and Reasons." American Journal of Obstetrics and Gynecology, 2020.
Saloranta TH, Gyllenberg FK, But A, et al. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons. Am J Obstet Gynecol. 2020.
Saloranta, T. H., Gyllenberg, F. K., But, A., Gissler, M., Laine, M. K., & Heikinheimo, O. (2020). Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2020.06.023
Saloranta TH, et al. Free-of-charge Long-acting Reversible Contraception: Two-year Discontinuation, Its Risk Factors, and Reasons. Am J Obstet Gynecol. 2020 Jun 17; PubMed PMID: 32562657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons. AU - Saloranta,Tuire H, AU - Gyllenberg,Frida K, AU - But,Anna, AU - Gissler,Mika, AU - Laine,Merja K, AU - Heikinheimo,Oskari, Y1 - 2020/06/17/ PY - 2019/10/08/received PY - 2020/05/07/revised PY - 2020/06/10/accepted PY - 2020/6/21/pubmed PY - 2020/6/21/medline PY - 2020/6/21/entrez KW - adverse effects KW - contraception KW - contraceptive implants KW - copper intrauterine devices KW - discontinuation KW - family planning KW - intrauterine devices KW - levonorgestrel-releasing intrauterine system JF - American journal of obstetrics and gynecology JO - Am. J. Obstet. Gynecol. N2 - BACKGROUND: Since 2013, the residents of the city of Vantaa, Finland, have been offered their first long-acting reversible contraceptive method (levonorgestrel-releasing intrauterine system, implant, and copper intrauterine device) free of charge. OBJECTIVE: The primary aim of this study was to assess the 2-year cumulative discontinuation rates of long-acting reversible contraceptive methods when provided free of charge for first-time users in a real-world setting. Additional aims were to describe factors associated with discontinuation and to evaluate the reasons for discontinuation. STUDY DESIGN: This is a retrospective register-based cohort study of 2026 nonsterilized women aged 15 to 44 years, who initiated a free-of-charge long-acting contraceptive method in 2013-2014 in the city of Vantaa. Removals within 2 years after method initiation and reasons for discontinuation were obtained from electronic health records and from national registers. We calculated the 2-year cumulative incidence rates of discontinuation with 95% confidence intervals for each method. Furthermore, we assessed crude and adjusted incidence rate ratios of discontinuation with 95% confidence interval by Poisson regression models comparing implants and copper intrauterine device with levonorgestrel-releasing intrauterine systems. RESULTS: During the 2 -year follow-up, 514 women discontinued, yielding a cumulative discontinuation rate of 28.3 per 100 women-years (95% confidence interval, 26.2-30.4). Among the 1199 women who initiated the levonorgestrel-releasing intrauterine system, the cumulative discontinuation rate was 24.2 per 100 women-years (95% confidence interval, 21.7-26.9); among the 642 implant users, 33.3 per 100 women-years (95% confidence interval, 29.5-37.4); and among the 185 copper intrauterine device users, 37.8 per 100 women-years (95% confidence interval, 31.0-45.7). Compared with women aged 30 to 44 years, women aged 15 to 19 years (adjusted incidence rate ratio, 1.58; 95% confidence interval, 1.17-2.14) and 20 to 29 years (adjusted incidence rate ratio, 1.35; 95% confidence interval, 1.11-1.63) were more likely to discontinue. We observed a higher discontinuation rate in women who had given birth within the previous year (adjusted incidence rate ratio, 1.36; 95% confidence interval, 1.13-1.65), spoke a native language other than Finnish or Swedish (adjusted incidence rate ratio, 1.31; 95% confidence interval, 1.06-1.63), and had a history of a sexually transmitted infection (adjusted incidence rate ratio, 1.62; 95% confidence interval, 1.07-2.46). No association was found in marital status, overall parity, history of induced abortion, socioeconomic status, education level, or smoking status. The most common reason for discontinuation was bleeding disturbances, reported by 21% of women who discontinued the levonorgestrel-releasing intrauterine system, by 71% who discontinued the implant, and by 41% who discontinued the copper intrauterine device. One in 4 women who discontinued the copper intrauterine device reported heavy menstrual bleeding, whereas only 1% who discontinued the levonorgestrel-releasing intrauterine system and none who discontinued implants reported this reason. Abdominal pain was the reported reason for discontinuation in 20% of both intrauterine device users and in only 2% who discontinued implants. CONCLUSION: At 2 years, the use of implants and copper intrauterine devices was more likely to be discontinued than that of the levonorgestrel-releasing intrauterine system. Women younger than 30 years and those who gave birth in the preceding year, spoke a native language other than Finnish or Swedish, or had a history of sexually transmitted infections were more likely to discontinue. The levonorgestrel-releasing intrauterine system was least likely to be removed owing to bleeding disturbances. SN - 1097-6868 UR - https://www.unboundmedicine.com/medline/citation/32562657/Long-Acting_Reversible_Contraception_Free-of-Charge:_Two-year_Discontinuation,_its_Risk_Factors_and_Reasons L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(20)30641-4 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.